by Eclosion Team | Sep 14, 2016 | Uncategorized
Therapeutic candidate GNbAC1 is first to target potential primary cause of MS Over 130 of 260 patients enrolled Clinical trial design presented during ECTRIMS Congress Primary data read-out confirmed in 4Q2017 Geneva, Switzerland, 14 September 2016 –GeNeuro (Euronext...